GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets
GSK plc (LSE: GSK; NYSE: GSK) heads into the weekend with a rare “everything-bagel” mix of catalysts: a new U.S. drug-pricing agreement tied to tariff relief, a fresh FDA approval that could reshape severe-asthma dosing schedules, expanding vaccine indications in Europe, and a steady drumbeat of buybacks. For investors tracking GSK stock, the headline isn’t just one event—it’s the way policy, pipeline, and capital returns are colliding in the same two-week window. Because December 20, 2025 is a Saturday, markets are closed. In U.S. trading, GSK’s ADR last closed on Friday, Dec. 19 at $48.61. StockAnalysis Below is a detailed